Clinical Trial

Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
Trial Details
NCT Number NCT07734597
Lead Sponsor GÜLDEN ANATACA
Conditions Polyneuropathies, Diabetic Complications Neurological, Diabetes Mellitus Type 2
Enrollment 81 participants
Start Date 2026-07-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-29